Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-FAPI vs 68Ga-DOTATATE PET/CT in NPC
NCT05990998Phase 2Completed
- Sponsor
- The First Hospital of Fujian Medical University
- Start
- Nov 2022
- Primary completion
- Aug 2023
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 68Ga-FAPI and gallium ga 68 dotatate in nasopharyngeal carcinoma (NPC), sponsored by The First Hospital of Fujian Medical University. Primary endpoints: Maximum Standardized Uptake Value at 2 years and Number of Lesions at 2 years. Started Nov 2022; status: completed.
02
Drugs
68Ga-FAPIgallium ga 68 dotatate
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT05990998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05990998.